What makes Tesamorelin notable in this blend?

Tesamorelin is the GHRH analog with the strongest clinical evidence for reducing visceral (deep abdominal) fat, which is why it is paired with Ipamorelin in metabolically focused research stacks.

How is this different from the triple Tesamorelin blend?

The two-part blend omits CJC-1295, relying on a single GHRH analog plus Ipamorelin, which is sometimes preferred in research for a simpler combination with fewer variables.

← All peptides

Growth Hormone Secretagogues

Weight & Metabolic

Research Chemical

Tesamorelin / Ipamorelin Blend

Also known as: Tesamorelin & Ipamorelin, Tesamorelin, Ipamorelin

A research blend combining the visceral-fat-reducing GHRH analog Tesamorelin with the selective ghrelin agonist Ipamorelin. It is studied for synergistic GH release with a favorable metabolic profile.

Mechanism of Action

Tesamorelin is a stabilized analog of GHRH that binds the pituitary GHRH receptor to increase pulsatile growth hormone secretion and has been clinically shown to reduce visceral adipose tissue. Ipamorelin selectively activates the GHS-R1a (ghrelin) receptor to evoke an additional GH pulse without significantly raising cortisol or prolactin. Acting through two distinct receptors, the combination produces a synergistic GH response while Tesamorelin contributes targeted lipolytic effects on visceral fat.

Half-life: Mixed: Tesamorelin ~26-38 minutes, Ipamorelin ~2 hours
Administration Routes: subcutaneous
Research Status: Research Chemical